Director at Kyverna Therapeutics (KYTX) granted options and RSUs

Rhea-AI Filing Summary

Kyverna Therapeutics director Emany Sravan Kumar received new equity awards. On February 24, 2026, Kumar was granted a stock option for 42,945 shares at an exercise price of $0.00 per share and 11,006 shares of common stock as a restricted stock unit award.

The restricted stock units are scheduled to vest in three equal annual installments on each one-year anniversary of the grant date, subject to continued service. The stock option is scheduled to vest in 36 equal monthly installments starting from the grant date, also conditioned on continued service to the company.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Emany Sravan Kumar

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	42,945	$0.00	--
Grant/Award	Common Stock	11,006	$0.00	--

Holdings After Transaction: Stock Option (right to buy) — 42,945 shares (Direct); Common Stock — 11,006 shares (Direct)

Footnotes (1)

1. Represents a restricted stock unit award of common stock and 1/3rd of the shares underlying the restricted stock unit award shall vest on each one-year anniversary of the date of grant, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive. 1/36th of the shares subject to the option shall vest on each monthly anniversary of the date of grant, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Emany Sravan Kumar

(Last) (First) (Middle)

C/O KYVERNA THERAPEUTICS, INC.

5980 HORTON ST., STE 550

(Street)

EMERYVILLE CA 94608

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Kyverna Therapeutics, Inc. [ KYTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/24/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/24/2026		A		11,006(1)	A	$0	11,006	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$7.95	02/24/2026		A		42,945		(2)	02/24/2036	Common Stock	42,945	$0	42,945	D

Explanation of Responses:

1. Represents a restricted stock unit award of common stock and 1/3rd of the shares underlying the restricted stock unit award shall vest on each one-year anniversary of the date of grant, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive.

2. 1/36th of the shares subject to the option shall vest on each monthly anniversary of the date of grant, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive.

	/s/ Marc Grasso, as Attorney-in-Fact	02/26/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Kyverna Therapeutics (KYTX) director Emany Sravan Kumar receive in this Form 4?

Kumar received equity awards consisting of a stock option and restricted stock units. The option covers 42,945 shares at a $0.00 exercise price, and 11,006 shares were granted as restricted stock units, all tied to continued service and scheduled vesting.

How many Kyverna Therapeutics (KYTX) shares are covered by the new stock option grant?

The stock option grant covers 42,945 shares of Kyverna common stock. According to the disclosure, the option was awarded at an exercise price of $0.00 per share and is structured to vest in equal monthly installments over a multi-year period, subject to continued service.

What are the vesting terms of the restricted stock units granted to the Kyverna (KYTX) director?

The restricted stock unit award of 11,006 Kyverna shares vests over three years. One-third of the shares vest on each one-year anniversary of the February 24, 2026 grant date, provided the director remains in continuous service on each applicable vesting date.

How does the stock option granted to the Kyverna (KYTX) director vest over time?

The option vests in 36 equal monthly installments beginning on the grant date. Specifically, 1/36th of the 42,945 underlying shares vest on each monthly anniversary of February 24, 2026, contingent on the director’s continued service to Kyverna through each vesting date.

Are the Kyverna (KYTX) equity awards in this Form 4 open-market purchases or compensation grants?

These are compensation-related grants, not open-market purchases. The Form 4 describes them as awards: a stock option and restricted stock units, both granted at $0.00 per share, with vesting schedules based on the director’s continued service to Kyverna.

How many Kyverna (KYTX) shares does the director hold after these equity awards?

After these awards, the director holds 42,945 shares subject to the stock option and 11,006 shares of common stock from the restricted stock unit grant. These positions reflect the totals reported following the transactions on February 24, 2026.